{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:48:38Z","timestamp":1755794918749,"version":"3.44.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,16]]},"DOI":"10.7759\/cureus.90214","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T12:40:23Z","timestamp":1755348023000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Perspectives on Stroke Prevention in Patients with Non-valvular Atrial Fibrillation in the Philippines"],"prefix":"10.7759","author":[{"given":"Rodney","family":"Jimenez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisa","family":"Bernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federick  C","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herminigildo H","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Victoria","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Ong-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jermaine","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.102181","article-title":"Atrial fibrillation and stroke: state-of-the-art and future directions","volume":"49","author":"Elsheikh S","year":"2024","unstructured":"Elsheikh S, Hill A, Irving G, Lip GY, Abdul-Rahim AH. Atrial fibrillation and stroke: state-of-the-art and future directions. Curr Probl Cardiol. 2024, 49:102181. 10.1016\/j.cpcardiol.2023.102181","journal-title":"Curr Probl Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100786","article-title":"Atrial fibrillation: epidemiology, screening and digital health","volume":"37","author":"Linz D","year":"2024","unstructured":"Linz D, Gawalko M, Betz K, et al.. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur. 2024, 37:100786. 10.1016\/j.lanepe.2023.100786","journal-title":"Lancet Reg Health Eur"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.069450","article-title":"Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities","volume":"125","author":"Rienstra M","year":"2012","unstructured":"Rienstra M, Lubitz SA, Mahida S, et al.. Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities. Circulation. 2012, 125:2933-43. 10.1161\/CIRCULATIONAHA.111.069450","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12051","article-title":"Global public awareness about atrial fibrillation","volume":"2","author":"Wendelboe AM","year":"2018","unstructured":"Wendelboe AM, Raskob GE, Angchaisuksiri P, et al.. Global public awareness about atrial fibrillation. Res Pract Thromb Haemost. 2018, 2:49-57. 10.1002\/rth2.12051","journal-title":"Res Pract Thromb Haemost"},{"key":"ref5","article-title":"The management of atrial fibrillation in the Philippines: a state-of-the-art review","volume":"80","author":"Fadreguilan E","year":"2023","unstructured":"Fadreguilan E. The management of atrial fibrillation in the Philippines: a state-of-the-art review. Philipp J Cardiol. 2023, 80:84.","journal-title":"Philipp J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.11909\/j.issn.1671-5411.2017.03.010","article-title":"Predisposing factors for atrial fibrillation in the elderly","volume":"14","author":"Wasmer K","year":"2017","unstructured":"Wasmer K, Eckardt L, Breithardt G. Predisposing factors for atrial fibrillation in the elderly. J Geriatr Cardiol. 2017, 14:179-84. 10.11909\/j.issn.1671-5411.2017.03.010","journal-title":"J Geriatr Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder IC","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al.. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024, 45:3314-414. 10.1093\/eurheartj\/ehae176","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-11334-z","article-title":"A scoping review of stroke services within the Philippines","volume":"24","author":"Logan A","year":"2024","unstructured":"Logan A, Faeldon L, Kent B, Ong A, Marsden J. A scoping review of stroke services within the Philippines. BMC Health Serv Res. 2024, 24:1006. 10.1186\/s12913-024-11334-z","journal-title":"BMC Health Serv Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.665086","article-title":"Current state of stroke care in the Philippines","volume":"12","author":"Collantes MV","year":"2021","unstructured":"Collantes MV, Zu\u00f1iga YH, Granada CN, et al.. Current state of stroke care in the Philippines. Front Neurol. 2021, 12:665086. 10.3389\/fneur.2021.665086","journal-title":"Front Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30506-2","article-title":"Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study","volume":"388","author":"O'Donnell MJ","year":"2016","unstructured":"O'Donnell MJ, Chin SL, Rangarajan S, et al.. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016, 388:761-75. 10.1016\/S0140-6736(16)30506-2","journal-title":"Lancet"},{"key":"ref11","article-title":"Prevalence of metabolic syndrome among adult Filipino patients with thyroid disease in an outpatient clinic in Cebu City, Philippines from 2004-2015","volume":"1","author":"Yu RM","year":"2017","unstructured":"Yu RM, Tan GH. Prevalence of metabolic syndrome among adult Filipino patients with thyroid disease in an outpatient clinic in Cebu City, Philippines from 2004-2015. J Diabetes Res Endocrinol. 2017, 1:1-7.","journal-title":"J Diabetes Res Endocrinol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.15605\/jafes.027.01.04","article-title":"The Philippine thyroid diseases study (PhilTiDeS 1): prevalence of thyroid disorders among adults in the Philippines","volume":"27","author":"Carlos-Raboca J","year":"2012","unstructured":"Carlos-Raboca J, Jimeno CA, Kho SA, et al.. The Philippine thyroid diseases study (PhilTiDeS 1): prevalence of thyroid disorders among adults in the Philippines. J ASEAN Fed Endocr Soc. 2012, 27:27-33.","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.577742","article-title":"Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study","volume":"41","author":"Sheu JJ","year":"2010","unstructured":"Sheu JJ, Kang JH, Lin HC, Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke. 2010, 41:961-6. 10.1161\/STROKEAHA.109.577742","journal-title":"Stroke"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051342","article-title":"Yearly incidence of stroke and bleeding in atrial fibrillation with concomitant hyperthyroidism: a national discharge database study","volume":"11","author":"Zhang J","year":"2022","unstructured":"Zhang J, Bisson A, Fauchier G, et al.. Yearly incidence of stroke and bleeding in atrial fibrillation with concomitant hyperthyroidism: a national discharge database study. J Clin Med. 2022, 11:10.3390\/jcm11051342","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620952550","article-title":"National physician survey for nonvalvular atrial fibrillation (NVAF) anticoagulation comparing knowledge, attitudes and practice of cardiologist to PCPs","volume":"26","author":"Saeed H","year":"2020","unstructured":"Saeed H, Ovalle OG, Bokhary U, et al.. National physician survey for nonvalvular atrial fibrillation (NVAF) anticoagulation comparing knowledge, attitudes and practice of cardiologist to PCPs. Clin Appl Thromb Hemost. 2020, 26:1076029620952550. 10.1177\/1076029620952550","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.21037\/acs-2023-afm-18","article-title":"Minimally invasive left atrial appendage occlusion plus reduced dose direct oral anticoagulant to prevent stroke in patients with atrial fibrillation-the LAAO-PlusRE","volume":"13","author":"Besola L","year":"2024","unstructured":"Besola L, Gregori D, Fiocco A, Colli A. Minimally invasive left atrial appendage occlusion plus reduced dose direct oral anticoagulant to prevent stroke in patients with atrial fibrillation-the LAAO-PlusRE. Ann Cardiothorac Surg. 2024, 13:146-54. 10.21037\/acs-2023-afm-18","journal-title":"Ann Cardiothorac Surg"},{"key":"ref17","unstructured":"Atrial fibrillation in the old\/very old. prevalence and burden, predisposing factors and complication. (2019). Accessed: May 20, 2025: https:\/\/www.escardio.org\/Journals\/E-Journal-of-Cardiology-Practice\/Volume-17\/Atrial-fibrillation-in-the-old-very-old-...."},{"key":"ref18","unstructured":"American Heart Association. Classes and stages of heart failure. (2025). Accessed. July 30, 2025: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/classes-of-heart-failure."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061698","article-title":"Poor time in therapeutic range control is associated with adverse clinical outcomes in patients with non-valvular atrial fibrillation: a report from the nationwide COOL-AF Registry","volume":"9","author":"Krittayaphong R","year":"2020","unstructured":"Krittayaphong R, Chantrarat T, Rojjarekampai R, Jittham P, Sairat P, Lip GY. Poor time in therapeutic range control is associated with adverse clinical outcomes in patients with non-valvular atrial fibrillation: a report from the nationwide COOL-AF Registry. J Clin Med. 2020, 9:1698. 10.3390\/jcm9061698","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/biom14040455","article-title":"Atrial fibrillation and dementia: pathophysiological mechanisms and clinical implications","volume":"14","author":"Varrias D","year":"2024","unstructured":"Varrias D, Saralidze T, Borkowski P, Pargaonkar S, Spanos M, Bazoukis G, Kokkinidis D. Atrial fibrillation and dementia: pathophysiological mechanisms and clinical implications. Biomolecules. 2024, 14:455. 10.3390\/biom14040455","journal-title":"Biomolecules"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1046351","article-title":"Stroke systems of care in the Philippines: Addressing gaps and developing strategies","volume":"13","author":"Collantes ME","year":"2022","unstructured":"Collantes ME, Navarro J, Belen A, Gan R. Stroke systems of care in the Philippines: Addressing gaps and developing strategies. Front Neurol. 2022, 13:1046351. 10.3389\/fneur.2022.1046351","journal-title":"Front Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.47895\/amp.vi0.1753","article-title":"Incidence and prevalence of stroke and its risk factors in the Philippines: a systematic review","volume":"56","author":"Collantes MEV","year":"2022","unstructured":"Collantes MEV, Zu\u00f1iga YMH, Uezono DR. Incidence and prevalence of stroke and its risk factors in the Philippines: a systematic review. Acta Med Philipp. 2022, 56:10.47895\/amp.vi0.1753","journal-title":"Acta Med Philipp"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/ijs.12287","article-title":"The real stroke burden in the Philippines","volume":"9","author":"Navarro JC","year":"2014","unstructured":"Navarro JC, Baroque AC 2nd, Lokin JK, Venketasubramanian N. The real stroke burden in the Philippines. Int J Stroke. 2014, 9:640-1. 10.1111\/ijs.12287","journal-title":"Int J Stroke"},{"key":"ref24","article-title":"Experiences and perspectives of Filipino patients with stroke on physical therapy telerehabilitation: a phenomenological study protocol","volume":"2","author":"Cruz CG","year":"2023","unstructured":"Cruz CG, Lipardo DS, Esplana NT, et al.. Experiences and perspectives of Filipino patients with stroke on physical therapy telerehabilitation: a phenomenological study protocol. Philipp J Phys Ther. 2023, 2:21-33.","journal-title":"Philipp J Phys Ther"},{"key":"ref25","unstructured":"Causes of deaths in the Philippines (preliminary). January to December 2020. (2020). Accessed: May 20, 2025: https:\/\/covidcalltohumanity.org\/wp-content\/uploads\/2021\/03\/Mapa_Causes-of-Deaths-in-the-Philippines-January-to-Decemb...."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000516238","article-title":"Stroke burden and services in the Philippines","volume":"11","author":"Navarro JC","year":"2021","unstructured":"Navarro JC, Venketasubramanian N. Stroke burden and services in the Philippines. Cerebrovasc Dis Extra. 2021, 11:52-4. 10.1159\/000516238","journal-title":"Cerebrovasc Dis Extra"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000357","article-title":"A call for a stroke referral network between primary care and stroke-ready hospitals in the Philippines: a narrative review","volume":"26","author":"Espiritu AI","year":"2021","unstructured":"Espiritu AI, San Jose MC. A call for a stroke referral network between primary care and stroke-ready hospitals in the Philippines: a narrative review. Neurologist. 2021, 26:253-60. 10.1097\/NRL.0000000000000357","journal-title":"Neurologist"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S61813","article-title":"Protocol for audit of current Filipino practice in rehabilitation of stroke inpatients","volume":"8","author":"Gonzalez-Suarez CB","year":"2015","unstructured":"Gonzalez-Suarez CB, Dizon JM, Grimmer K, et al.. Protocol for audit of current Filipino practice in rehabilitation of stroke inpatients. J Multidiscip Healthc. 2015, 8:127-38. 10.2147\/JMDH.S61813","journal-title":"J Multidiscip Healthc"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.22605\/RRH220","article-title":"Overview of devolution of health services in the Philippines","volume":"3","author":"Grundy J","year":"2003","unstructured":"Grundy J, Healy V, Gorgolon L, Sandig E. Overview of devolution of health services in the Philippines. Rural Remote Health. 2003, 3:220. 10.22605\/RRH220","journal-title":"Rural Remote Health"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034778","article-title":"Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies","volume":"10","author":"Salmasi S","year":"2020","unstructured":"Salmasi S, Loewen PS, Tandun R, Andrade JG, De Vera MA. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ Open. 2020, 10:e034778. 10.1136\/bmjopen-2019-034778","journal-title":"BMJ Open"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel J","year":"2021","unstructured":"Steffel J, Collins R, Antz M, et al.. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021, 23:1612-76. 10.1093\/europace\/euab065","journal-title":"Europace"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons","volume":"140","author":"January CT","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al.. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019, 140:e125-51. 10.1161\/CIR.0000000000000665","journal-title":"Circulation"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw058","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"38","author":"Heidbuchel H","year":"2017","unstructured":"Heidbuchel H, Verhamme P, Alings M, et al.. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2017, 38:2137-49. 10.1093\/eurheartj\/ehw058","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005969","article-title":"Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"13","author":"Ozaki AF","year":"2020","unstructured":"Ozaki AF, Choi AS, Le QT, Ko DT, Han JK, Park SS, Jackevicius CA. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2020, 13:e005969. 10.1161\/CIRCOUTCOMES.119.005969","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.5.430","article-title":"Real-world health care costs based on medication adherence and risk of stroke and bleeding in patients treated with novel anticoagulant therapy","volume":"24","author":"Deshpande CG","year":"2018","unstructured":"Deshpande CG, Kogut S, Willey C. Real-world health care costs based on medication adherence and risk of stroke and bleeding in patients treated with novel anticoagulant therapy. J Manag Care Spec Pharm. 2018, 24:430-9. 10.18553\/jmcp.2018.24.5.430","journal-title":"J Manag Care Spec Pharm"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.47895\/amp.vi0.6751","article-title":"Prognostic impact of atrial fibrillation pattern and other clinical biomarkers in patients with stroke admitted in a tertiary hospital in Cebu city from 2015-2022","volume":"58","author":"Im SM","year":"2024","unstructured":"Im SM, Ca\u00f1ete MT. Prognostic impact of atrial fibrillation pattern and other clinical biomarkers in patients with stroke admitted in a tertiary hospital in Cebu city from 2015-2022. Acta Med Philipp. 2024, 58:52-8. 10.47895\/amp.vi0.6751","journal-title":"Acta Med Philipp"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104586","article-title":"Gaps and challenges in the management of atrial fibrillation in the Philippines","volume":"82","author":"Ceriales JA","year":"2022","unstructured":"Ceriales JA, Cando LF, Callanta ML, Tantengco OA. Gaps and challenges in the management of atrial fibrillation in the Philippines. Ann Med Surg (Lond). 2022, 82:104586. 10.1016\/j.amsu.2022.104586","journal-title":"Ann Med Surg (Lond)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/ajag.13271","article-title":"Stroke in the very old: a study from the Philippine Neurological Association One Database","volume":"43","author":"Ca\u00f1ete MT","year":"2024","unstructured":"Ca\u00f1ete MT, Im S, Pascual JL, Gan R. Stroke in the very old: a study from the Philippine Neurological Association One Database. Australas J Ageing. 2024, 43:409-14. 10.1111\/ajag.13271","journal-title":"Australas J Ageing"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.5114\/ppn.2023.126482","article-title":"Family history of stroke - a useful clue for the primary care physician and stroke neurologist: a narrative review","volume":"32","author":"B\u0142a\u017c M","year":"2023","unstructured":"B\u0142a\u017c M, Sarzy\u0144ska-D\u0142ugosz I. Family history of stroke - a useful clue for the primary care physician and stroke neurologist: a narrative review. Postep Psychiatr Neurol. 2023, 32:31-9. 10.5114\/ppn.2023.126482","journal-title":"Postep Psychiatr Neurol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00054","article-title":"Stroke and bleeding risk assessments in patients with atrial fibrillation: concepts and controversies","volume":"7","author":"Ding WY","year":"2020","unstructured":"Ding WY, Harrison S, Gupta D, Lip GY, Lane DA. Stroke and bleeding risk assessments in patients with atrial fibrillation: concepts and controversies. Front Med (Lausanne). 2020, 7:54. 10.3389\/fmed.2020.00054","journal-title":"Front Med (Lausanne)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/genes13010048","article-title":"Ischemic stroke genetics: what is new and how to apply it in clinical practice?","volume":"13","author":"Ekkert A","year":"2021","unstructured":"Ekkert A, \u0160liachtenko A, Grigait\u0117 J, Burnyt\u0117 B, Utkus A, Jatu\u017eis D. Ischemic stroke genetics: what is new and how to apply it in clinical practice?. Genes (Basel). 2021, 13:48. 10.3390\/genes13010048","journal-title":"Genes (Basel)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suz066","article-title":"May Measurement Month 2017: an analysis of blood pressure screening in the Philippines-South-East Asia and Australasia","volume":"21","author":"Castillo RR","year":"2019","unstructured":"Castillo RR, Atilano AA, David-Ona DI, et al.. May Measurement Month 2017: an analysis of blood pressure screening in the Philippines-South-East Asia and Australasia. Eur Heart J Suppl. 2019, 21:D92-6. 10.1093\/eurheartj\/suz066","journal-title":"Eur Heart J Suppl"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101188","article-title":"Missed opportunities for hypertension screening of older people in the Philippines: cross-sectional analysis of nationally representative individual-level data","volume":"50","author":"Kraft AD","year":"2024","unstructured":"Kraft AD, Capuno JJ, Calicdan KG, Cruz GT, O'Donnell O. Missed opportunities for hypertension screening of older people in the Philippines: cross-sectional analysis of nationally representative individual-level data. Lancet Reg Health West Pac. 2024, 50:101188. 10.1016\/j.lanwpc.2024.101188","journal-title":"Lancet Reg Health West Pac"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1177\/17474930241302272","article-title":"ECG-based machine learning model for AF identification in patients with first ischemic stroke","volume":"20","author":"Yu CC","year":"2025","unstructured":"Yu CC, Peng YQ, Lin C, et al.. ECG-based machine learning model for AF identification in patients with first ischemic stroke. Int J Stroke. 2025, 20:411-8. 10.1177\/17474930241302272","journal-title":"Int J Stroke"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016560","article-title":"Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant)","volume":"98","author":"Ga\u017eov\u00e1 A","year":"2019","unstructured":"Ga\u017eov\u00e1 A, Leddy JJ, Rexov\u00e1 M, Hliv\u00e1k P, Hatala R, Kyselovi\u010d J. Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). Medicine (Baltimore). 2019, 98:e16560. 10.1097\/MD.0000000000016560","journal-title":"Medicine (Baltimore)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae281","article-title":"CHA2DS2-VA instead of CHA2DS2-VASc for stroke risk stratification in patients with atrial fibrillation: not just a matter of sex","volume":"26","author":"Boriani G","year":"2024","unstructured":"Boriani G, Vitolo M, Mei DA. CHA2DS2-VA instead of CHA2DS2-VASc for stroke risk stratification in patients with atrial fibrillation: not just a matter of sex. Europace. 2024, 26:281. 10.1093\/europace\/euae281","journal-title":"Europace"},{"key":"ref47","unstructured":"Risk factors for stroke. (2024). Accessed. May 20, 2025: https:\/\/www.cdc.gov\/stroke\/risk-factors\/index.html."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.12.042","article-title":"Racial and ethnic disparities in hospital mortality among ischemic stroke patients in Hawaii","volume":"27","author":"Ideta TR","year":"2018","unstructured":"Ideta TR, Lim E, Nakagawa K, Koenig MA. Racial and ethnic disparities in hospital mortality among ischemic stroke patients in Hawaii. J Stroke Cerebrovasc Dis. 2018, 27:1458-65. 10.1016\/j.jstrokecerebrovasdis.2017.12.042","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1397-3","article-title":"Socioeconomic status and stroke incidence, prevalence, mortality, and worldwide burden: an ecological analysis from the Global Burden of Disease Study 2017","volume":"17","author":"Avan A","year":"2019","unstructured":"Avan A, Digaleh H, Di Napoli M, et al.. Socioeconomic status and stroke incidence, prevalence, mortality, and worldwide burden: an ecological analysis from the Global Burden of Disease Study 2017. BMC Med. 2019, 17:191. 10.1186\/s12916-019-1397-3","journal-title":"BMC Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92172-5","article-title":"A new deep learning algorithm of 12-lead electrocardiogram for identifying atrial fibrillation during sinus rhythm","volume":"11","author":"Baek YS","year":"2021","unstructured":"Baek YS, Lee SC, Choi W, Kim DH. A new deep learning algorithm of 12-lead electrocardiogram for identifying atrial fibrillation during sinus rhythm. Sci Rep. 2021, 11:12818. 10.1038\/s41598-021-92172-5","journal-title":"Sci Rep"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.836609","article-title":"Bubble test and carotid ultrasound to guide indication of transesophageal echocardiography in young patients with stroke","volume":"13","author":"Mayerhofer E","year":"2022","unstructured":"Mayerhofer E, Kanz D, Guschlbauer B, et al..  Bubble test and carotid ultrasound to guide indication of transesophageal echocardiography in young patients with stroke. Front Neurol. 2022, 13:836609. 10.3389\/fneur.2022.836609","journal-title":"Front Neurol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044126","article-title":"Accuracy of Apple watch for detection of atrial fibrillation","volume":"141","author":"Seshadri DR","year":"2020","unstructured":"Seshadri DR, Bittel B, Browsky D, Houghtaling P, Drummond CK, Desai MY, Gillinov AM. Accuracy of Apple watch for detection of atrial fibrillation. Circulation. 2020, 141:702-3. 10.1161\/CIRCULATIONAHA.119.044126","journal-title":"Circulation"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2024.07.004","article-title":"Predictors of paroxysmal atrial fibrillation in patients with a cryptogenic stroke: selecting patients for long-term rhythm monitoring","volume":"22","author":"Apple SJ","year":"2025","unstructured":"Apple SJ, Parker M, Flomenbaum D, et al.. Predictors of paroxysmal atrial fibrillation in patients with a cryptogenic stroke: selecting patients for long-term rhythm monitoring. Heart Rhythm. 2025, 22:13-20. 10.1016\/j.hrthm.2024.07.004","journal-title":"Heart Rhythm"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.15420\/aer.2022.31","article-title":"Artificial intelligence for the detection and treatment of atrial fibrillation","volume":"12","author":"Harmon DM","year":"2023","unstructured":"Harmon DM, Sehrawat O, Maanja M, Wight J, Noseworthy PA. Artificial intelligence for the detection and treatment of atrial fibrillation. Arrhythm Electrophysiol Rev. 2023, 12:e12. 10.15420\/aer.2022.31","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2020.05.015","article-title":"Diagnostic accuracy of smart gadgets\/wearable devices in detecting atrial fibrillation: a systematic review and meta-analysis","volume":"114","author":"Prasitlumkum N","year":"2021","unstructured":"Prasitlumkum N, Cheungpasitporn W, Chokesuwattanaskul A, et al.. Diagnostic accuracy of smart gadgets\/wearable devices in detecting atrial fibrillation: a systematic review and meta-analysis. Arch Cardiovasc Dis. 2021, 114:4-16. 10.1016\/j.acvd.2020.05.015","journal-title":"Arch Cardiovasc Dis"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1032736","article-title":"Finding low CHA2DS2-VASc scores unreliable? Why not give morphological and hemodynamic methods a try?","volume":"9","author":"Sun Y","year":"2022","unstructured":"Sun Y, Ling Y, Chen Z, Wang Z, Li T, Tong Q, Qian Y. Finding low CHA2DS2-VASc scores unreliable? Why not give morphological and hemodynamic methods a try?. Front Cardiovasc Med. 2022, 9:1032736. 10.3389\/fcvm.2022.1032736","journal-title":"Front Cardiovasc Med"},{"key":"ref57","unstructured":"Predicting risk with oral anticoagulants. (2021). Accessed. May 24, 2025: https:\/\/www.nps.org.au\/news\/predicting-risk-with-oral-anticoagulants."},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.15420\/aer.2015.04.02.100","article-title":"Anticoagulation in atrial fibrillation - current concepts","volume":"4","author":"Katritsis DG","year":"2015","unstructured":"Katritsis DG, Gersh BJ, Camm AJ. Anticoagulation in atrial fibrillation - current concepts. Arrhythm Electrophysiol Rev. 2015, 4:100-7. 10.15420\/aer.2015.04.02.100","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1097\/JNN.0000000000000085","article-title":"Oral anticoagulants: the move beyond warfarin","volume":"46","author":"Frei J","year":"2014","unstructured":"Frei J, Carroll VS. Oral anticoagulants: the move beyond warfarin. J Neurosci Nurs. 2014, 46:253-5. 10.1097\/JNN.0000000000000085","journal-title":"J Neurosci Nurs"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-011-0050-4","article-title":"Blood biomarkers of ischemic stroke","volume":"8","author":"Jickling GC","year":"2011","unstructured":"Jickling GC, Sharp FR. Blood biomarkers of ischemic stroke. Neurotherapeutics. 2011, 8:349-60. 10.1007\/s13311-011-0050-4","journal-title":"Neurotherapeutics"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.029232","article-title":"Role of blood-based biomarkers in ischemic stroke prognosis: a systematic review","volume":"52","author":"Montellano FA","year":"2021","unstructured":"Montellano FA, Ungeth\u00fcm K, Ramiro L, et al.. Role of blood-based biomarkers in ischemic stroke prognosis: a systematic review. Stroke. 2021, 52:543-51. 10.1161\/STROKEAHA.120.029232","journal-title":"Stroke"},{"key":"ref62","article-title":"Management of acute ischemic stroke: time is brain","volume":"107","author":"Rymner MM","year":"2010","unstructured":"Rymner MM, Akhtar N, Martin C, Summers D. Management of acute ischemic stroke: time is brain. Mo Med. 2010, 107:333-7.","journal-title":"Mo Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52927","article-title":"Trends in stroke thrombolysis care metrics and outcomes by race and ethnicity, 2003-2021","volume":"7","author":"Man S","year":"2024","unstructured":"Man S, Solomon N, Mac Grory B, et al.. Trends in stroke thrombolysis care metrics and outcomes by race and ethnicity, 2003-2021. JAMA Netw Open. 2024, 7:e2352927. 10.1001\/jamanetworkopen.2023.52927","journal-title":"JAMA Netw Open"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-020-01163-4","article-title":"Tight versus standard blood pressure control on the incidence of myocardial infarction and stroke: an observational retrospective cohort study in the general ambulatory setting","volume":"21","author":"Park B","year":"2020","unstructured":"Park B, Budzynska K, Almasri N, et al.. Tight versus standard blood pressure control on the incidence of myocardial infarction and stroke: an observational retrospective cohort study in the general ambulatory setting. BMC Fam Pract. 2020, 21:91. 10.1186\/s12875-020-01163-4","journal-title":"BMC Fam Pract"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1177\/1941874416630029","article-title":"Management of acute hypertensive response in patients with ischemic stroke","volume":"6","author":"AlSibai A","year":"2016","unstructured":"AlSibai A, Qureshi AI. Management of acute hypertensive response in patients with ischemic stroke. Neurohospitalist. 2016, 6:122-9. 10.1177\/1941874416630029","journal-title":"Neurohospitalist"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American","volume":"52","author":"Kleindorfer DO","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, et al.. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American. Stroke. 2021, 52:e364-467. 10.1161\/STR.0000000000000375","journal-title":"Stroke"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000475","article-title":"2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association\/American Stroke Association","volume":"55","author":"Bushnell C","year":"2024","unstructured":"Bushnell C, Kernan WN, Sharrief AZ, et al.. 2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2024, 55:e344-424. 10.1161\/STR.0000000000000475","journal-title":"Stroke"},{"key":"ref68","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2021.1930137","article-title":"Rate control strategies for atrial fibrillation","volume":"53","author":"Alobaida M","year":"2021","unstructured":"Alobaida M, Alrumayh A. Rate control strategies for atrial fibrillation. Ann Med. 2021, 53:682-92.","journal-title":"Ann Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.978637","article-title":"Early rhythm control vs. rate control in atrial fibrillation: a systematic review and meta-analysis","volume":"10","author":"Han S","year":"2023","unstructured":"Han S, Jia R, Cen Z, et al.. Early rhythm control vs. rate control in atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med. 2023, 10:978637. 10.3389\/fcvm.2023.978637","journal-title":"Front Cardiovasc Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000152","article-title":"Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"48","author":"Yaghi S","year":"2017","unstructured":"Yaghi S, Willey JZ, Cucchiara B, et al.. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2017, 48:e343-61. 10.1161\/STR.0000000000000152","journal-title":"Stroke"},{"key":"ref71","unstructured":"FDA. Eliquis (apixaban). Highlights of prescribing information. (2012). Accessed. May 20, 2025: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf."},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack CV Jr","year":"2017","unstructured":"Pollack CV Jr, Reilly PA, van Ryn J, et al.. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017, 377:431-41. 10.1056\/NEJMoa1707278","journal-title":"N Engl J Med"},{"key":"ref73","article-title":"Current patterns in the management of adult stroke by Filipino neurologists: a nationwide cross-sectional survey among fellows of the Philippine neurological association","volume":"51","author":"Roxas Jr AA","year":"2017","unstructured":"Roxas Jr AA, Bautista RL. Current patterns in the management of adult stroke by Filipino neurologists: a nationwide cross-sectional survey among fellows of the Philippine neurological association. Acta Medica Philippinia. 2017, 51:92-9.","journal-title":"Acta Medica Philippinia"},{"key":"ref74","unstructured":"Clinical practice guidelines on the management of acute ischemic stroke and intracerebral 1 hemorrhage in the Philippines. (2024). Accessed. May 24, 2025: http:\/\/www.strokesocietyphilippines.org\/wp-content\/uploads\/2024\/07\/CPG2024.pdf."},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1177\/1747493020906872","article-title":"Cost of hospitalization for stroke in a low-middle-income country: findings from a public tertiary hospital in the Philippines","volume":"16","author":"Diestro JD","year":"2021","unstructured":"Diestro JD, Omar AT, Sarmiento RJ, et al.. Cost of hospitalization for stroke in a low-middle-income country: findings from a public tertiary hospital in the Philippines. Int J Stroke. 2021, 16:39-42. 10.1177\/1747493020906872","journal-title":"Int J Stroke"},{"key":"ref76","unstructured":"Implementing guidelines on the case rates for acute stroke. (2023). Accessed. January 28, 2025: https:\/\/www.philhealth.gov.ph\/circulars\/2023\/PC2023-0021.pdf."},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1177\/2047487314540386","article-title":"Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: the PURE study","volume":"22","author":"Gupta R","year":"2015","unstructured":"Gupta R, Islam S, Mony P, et al.. Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: the PURE study. Eur J Prev Cardiol. 2015, 22:1261-71. 10.1177\/2047487314540386","journal-title":"Eur J Prev Cardiol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S235107","article-title":"The association among medication beliefs, perception of illness and medication adherence in ischemic stroke patients: a cross-sectional study in China","volume":"14","author":"Ruksakulpiwat S","year":"2020","unstructured":"Ruksakulpiwat S, Liu Z, Yue S, Fan Y. The association among medication beliefs, perception of illness and medication adherence in ischemic stroke patients: a cross-sectional study in China. Patient Prefer Adherence. 2020, 14:235-47. 10.2147\/PPA.S235107","journal-title":"Patient Prefer Adherence"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.5530\/ijopp.15.2.16","article-title":"Determination of barriers in medication adherence for secondary prevention in stroke patients","volume":"15","author":"Velusamy S","year":"2022","unstructured":"Velusamy S, Varatharaj K, Kathirvel R, Venkatesan P, Varghese LJ. Determination of barriers in medication adherence for secondary prevention in stroke patients. IJOPP. 2022, 15:83-9. 10.5530\/ijopp.15.2.16","journal-title":"IJOPP"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssmqr.2022.100104","article-title":"Strong structuration analysis of patterns of adherence to hypertension medication","volume":"2","author":"Seguin M","year":"2022","unstructured":"Seguin M, Mendoza J, Lasco G, et al.. Strong structuration analysis of patterns of adherence to hypertension medication. SSM Qual Res Health. 2022, 2:100104. 10.1016\/j.ssmqr.2022.100104","journal-title":"SSM Qual Res Health"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-012-2308-x","article-title":"Key barriers to medication adherence in survivors of strokes and transient ischemic attacks","volume":"28","author":"Kronish IM","year":"2013","unstructured":"Kronish IM, Diefenbach MA, Edmondson DE, Phillips LA, Fei K, Horowitz CR. Key barriers to medication adherence in survivors of strokes and transient ischemic attacks. J Gen Intern Med. 2013, 28:675-82. 10.1007\/s11606-012-2308-x","journal-title":"J Gen Intern Med"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S420059","article-title":"Utilizing social determinants of health model to understand barriers to medication adherence in patients with ischemic stroke: a systematic review","volume":"17","author":"Ruksakulpiwat S","year":"2023","unstructured":"Ruksakulpiwat S, Benjasirisan C, Ding K, et al..  Utilizing social determinants of health model to understand barriers to medication adherence in patients with ischemic stroke: a systematic review. Patient Prefer Adherence. 2023, 17:2161-74. 10.2147\/PPA.S420059","journal-title":"Patient Prefer Adherence"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab021","article-title":"Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?","volume":"29","author":"Papakonstantinou PE","year":"2022","unstructured":"Papakonstantinou PE, Borovac JA, G\u0105secka A, et al.. Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?. Eur J Prev Cardiol. 2022, 29:2069-71. 10.1093\/eurjpc\/zwab021","journal-title":"Eur J Prev Cardiol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2069176","article-title":"Vitamin K and bone health: a review on the effects of vitamin k deficiency and supplementation and the effect of non-vitamin k antagonist oral anticoagulants on different bone parameters","volume":"2019","author":"Rodr\u00edguez-Olleros Rodr\u00edguez C","year":"2019","unstructured":"Rodr\u00edguez-Olleros Rodr\u00edguez C, D\u00edaz Curiel M. Vitamin K and bone health: a review on the effects of vitamin k deficiency and supplementation and the effect of non-vitamin k antagonist oral anticoagulants on different bone parameters. J Osteoporos. 2019, 2019:2069176. 10.1155\/2019\/2069176","journal-title":"J Osteoporos"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suab152","article-title":"Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation","volume":"24","author":"Farinha JM","year":"2022","unstructured":"Farinha JM, Jones ID, Lip GY. Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation. Eur Heart J Suppl. 2022, 24:A42-55. 10.1093\/eurheartj\/suab152","journal-title":"Eur Heart J Suppl"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian A","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, et al.. 2021 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022, 43:561-632. 10.1093\/eurheartj\/ehab395","journal-title":"Eur Heart J"},{"key":"ref87","doi-asserted-by":"crossref","DOI":"10.1186\/s43094-020-00114-1","article-title":"NOACs: an emerging class of oral anticoagulants-a review article","volume":"6","author":"Paul C","year":"2020","unstructured":"Paul C, Baby M, Anthraper AR, Krishnakumar K. NOACs: an emerging class of oral anticoagulants-a review article. Futur J Pharm Sci. 2020, 6:1-7.","journal-title":"Futur J Pharm Sci"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.3390\/cells11203214","article-title":"Anticoagulants: a short history, their mechanism of action, pharmacology, and indications","volume":"11","author":"Heestermans M","year":"2022","unstructured":"Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L. Anticoagulants: a short history, their mechanism of action, pharmacology, and indications. Cells. 2022, 11:3214. 10.3390\/cells11203214","journal-title":"Cells"},{"key":"ref89","unstructured":"Xagulant 2.5\/Xagulant 5. (2025). Accessed. March 3, 2025: https:\/\/www.mims.com\/philippines\/drug\/info\/xagulant-2-5-xagulant-5?type=full."},{"key":"ref90","unstructured":"Xarelto. Rivaroxaban. (2025). Accessed. March 3, 2025: http:\/\/www.mims.com\/philippines\/drug\/info\/xarelto?type=full."},{"key":"ref91","unstructured":"Lixiana. Edoxaban. (2025). Accessed. March 3, 2025: https:\/\/www.mims.com\/philippines\/drug\/info\/lixiana."},{"key":"ref92","unstructured":"Pradaxa. Dabigatran. (2025). Accessed. March 3, 2025: https:\/\/www.mims.com\/philippines\/drug\/info\/pradaxa?type=full."},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al.. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365:981-92. 10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al.. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361:1139-51. 10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly SJ","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, et al.. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011, 364:806-17. 10.1056\/NEJMoa1007432","journal-title":"N Engl J Med"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff CT","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al.. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014, 383:955-62. 10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.10.002","article-title":"A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens","volume":"134","author":"Provid\u00eancia R","year":"2014","unstructured":"Provid\u00eancia R, Grove EL, Husted S, Barra S, Boveda S, Morais J. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thromb Res. 2014, 134:1253-64. 10.1016\/j.thromres.2014.10.002","journal-title":"Thromb Res"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey GJ","year":"2012","unstructured":"Hankey GJ, Patel MR, Stevens SR, et al.. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012, 11:315-22. 10.1016\/S1474-4422(12)70042-X","journal-title":"Lancet Neurol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener HC","year":"2010","unstructured":"Diener HC, Connolly SJ, Ezekowitz MD, et al.. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010, 9:1157-63. 10.1016\/S1474-4422(10)70274-X","journal-title":"Lancet Neurol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.025554","article-title":"Risks of stroke and mortality in atrial fibrillation patients treated with rivaroxaban and warfarin","volume":"51","author":"Alberts M","year":"2020","unstructured":"Alberts M, Chen YW, Lin JH, Kogan E, Twyman K, Milentijevic D. Risks of stroke and mortality in atrial fibrillation patients treated with rivaroxaban and warfarin. Stroke. 2020, 51:549-55. 10.1161\/STROKEAHA.119.025554","journal-title":"Stroke"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen TB","year":"2016","unstructured":"Larsen TB, Skj\u00f8th F, Nielsen PB, Kj\u00e6ldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016, 353:i3189. 10.1136\/bmj.i3189","journal-title":"BMJ"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2023.24","article-title":"Selection of non-vitamin k antagonist oral anticoagulant for stroke prevention in atrial fibrillation based on patient profile: perspectives from Vietnamese experts. Part 1","volume":"18","author":"Quang Ho TH","year":"2023","unstructured":"Quang Ho TH, Ton MT, Nguyen VL, et al.. Selection of non-vitamin k antagonist oral anticoagulant for stroke prevention in atrial fibrillation based on patient profile: perspectives from Vietnamese experts. Part 1. Eur Cardiol. 2023, 18:e61. 10.15420\/ecr.2023.24","journal-title":"Eur Cardiol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.09.19","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"5","author":"Khan AA","year":"2017","unstructured":"Khan AA, Lip GY. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. Ann Transl Med. 2017, 5:465. 10.21037\/atm.2017.09.19","journal-title":"Ann Transl Med"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz952","article-title":"Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study","volume":"41","author":"Huang HK","year":"2020","unstructured":"Huang HK, Liu PP, Hsu JY, Lin SM, Peng CC, Wang JH, Loh CH. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study. Eur Heart J. 2020, 41:1100-8. 10.1093\/eurheartj\/ehz952","journal-title":"Eur Heart J"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14243","article-title":"Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: a nationwide cohort study","volume":"23","author":"Huang HK","year":"2021","unstructured":"Huang HK, Liu PP, Lin SM, et al.. Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: a nationwide cohort study. Diabetes Obes Metab. 2021, 23:499-507. 10.1111\/dom.14243","journal-title":"Diabetes Obes Metab"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-12-1000","article-title":"Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation","volume":"116","author":"Kittelson JM","year":"2016","unstructured":"Kittelson JM, Steg PG, Halperin JL, et al.. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2016, 116:544-53. 10.1160\/TH15-12-1000","journal-title":"Thromb Haemost"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066485","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten LP","year":"2024","unstructured":"Joosten LP, van Doorn S, van de Ven PM, et al.. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation. 2024, 149:279-89. 10.1161\/CIRCULATIONAHA.123.066485","journal-title":"Circulation"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.030761","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and prior gastrointestinal bleeding","volume":"52","author":"Kwon S","year":"2021","unstructured":"Kwon S, Lee SR, Choi EK, et al.. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and prior gastrointestinal bleeding. Stroke. 2021, 52:511-20. 10.1161\/STROKEAHA.120.030761","journal-title":"Stroke"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.01.224","article-title":"Atrial fibrillation increases the risk of all-cause dementia, Alzheimer's disease, and vascular dementia: a cohort study of 373, 415 participants in the UK Biobank","volume":"351","author":"Zhai Y","year":"2024","unstructured":"Zhai Y, Hu F, Yuan L, et al.. Atrial fibrillation increases the risk of all-cause dementia, Alzheimer's disease, and vascular dementia: a cohort study of 373, 415 participants in the UK Biobank. J Affect Disord. 2024, 351:323-30. 10.1016\/j.jad.2024.01.224","journal-title":"J Affect Disord"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028290","article-title":"Incident atrial fibrillation and risk of dementia in a diverse, community-based population","volume":"12","author":"Bansal N","year":"2023","unstructured":"Bansal N, Zelnick LR, An J, et al.. Incident atrial fibrillation and risk of dementia in a diverse, community-based population. J Am Heart Assoc. 2023, 12:e028290. 10.1161\/JAHA.122.028290","journal-title":"J Am Heart Assoc"},{"key":"ref111","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.121.055018","article-title":"Atrial fibrillation and dementia: a report from the AF-SCREEN International Collaboration","volume":"145","author":"Rivard L","year":"2022","unstructured":"Rivard L, Friberg L, Conen D, et al.. Atrial fibrillation and dementia: a report from the AF-SCREEN International Collaboration. Circulation. 2022, 145:392-409.","journal-title":"Circulation"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2023.01.005","article-title":"Atrial fibrillation and the risk of early-onset dementia and cognitive decline: an updated review","volume":"34","author":"Kogelschatz B","year":"2024","unstructured":"Kogelschatz B, Zenger B, Steinberg BA, Ranjan R, Jared Bunch T. Atrial fibrillation and the risk of early-onset dementia and cognitive decline: an updated review. Trends Cardiovasc Med. 2024, 34:236-41. 10.1016\/j.tcm.2023.01.005","journal-title":"Trends Cardiovasc Med"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02440-1","article-title":"Effectiveness and safety of apixaban vs warfarin in patients with venous thromboembolism with risk factors for bleeding or for recurrences","volume":"40","author":"Cohen AT","year":"2023","unstructured":"Cohen AT, Sah J, Dhamane AD, et al.. Effectiveness and safety of apixaban vs warfarin in patients with venous thromboembolism with risk factors for bleeding or for recurrences. Adv Ther. 2023, 40:1705-35. 10.1007\/s12325-023-02440-1","journal-title":"Adv Ther"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2505","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care","volume":"362","author":"Vinogradova Y","year":"2018","unstructured":"Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018, 362:k2505. 10.1136\/bmj.k2505","journal-title":"BMJ"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.7326\/M23-3067","article-title":"Comparative effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation: a nationwide cohort study","volume":"177","author":"Simon TG","year":"2024","unstructured":"Simon TG, Singer DE, Zhang Y, Mastrorilli JM, Cervone A, DiCesare E, Lin KJ. Comparative effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation: a nationwide cohort study. Ann Intern Med. 2024, 177:1028-38. 10.7326\/M23-3067","journal-title":"Ann Intern Med"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly SJ","year":"2022","unstructured":"Connolly SJ, Karthikeyan G, Ntsekhe M, et al.. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022, 387:978-88. 10.1056\/NEJMoa2209051","journal-title":"N Engl J Med"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom JW","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, et al.. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013, 369:1206-14. 10.1056\/NEJMoa1300615","journal-title":"N Engl J Med"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an on-x mechanical aortic valve","volume":"2","author":"Wang TY","year":"2023","unstructured":"Wang TY, Svensson LG, Wen J, et al.. Apixaban or warfarin in patients with an on-x mechanical aortic valve. NEJM Evid. 2023, 2:EVIDoa2300067. 10.1056\/EVIDoa2300067","journal-title":"NEJM Evid"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1099591","article-title":"Safety and efficacy of direct oral anticoagulants in bioprosthetic valves: a systematic review and meta-analysis","volume":"10","author":"Bakr L","year":"2023","unstructured":"Bakr L, Elsayed A, Saleh O, Abdalraouf M, Ng GA, Ibrahim M. Safety and efficacy of direct oral anticoagulants in bioprosthetic valves: a systematic review and meta-analysis. Front Cardiovasc Med. 2023, 10:1099591. 10.3389\/fcvm.2023.1099591","journal-title":"Front Cardiovasc Med"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221103578","article-title":"DOACs in mechanical and bioprosthetic heart valves: a narrative review of emerging data and future directions","volume":"28","author":"Ryu R","year":"2022","unstructured":"Ryu R, Tran R. DOACs in mechanical and bioprosthetic heart valves: a narrative review of emerging data and future directions. Clin Appl Thromb Hemost. 2022, 28:10.1177\/10760296221103578","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2021.02.002","article-title":"Outcomes of direct oral anticoagulants in atrial fibrillation patients across different body mass index categories","volume":"7","author":"Barakat AF","year":"2021","unstructured":"Barakat AF, Jain S, Masri A, et al.. Outcomes of direct oral anticoagulants in atrial fibrillation patients across different body mass index categories. JACC Clin Electrophysiol. 2021, 7:649-58. 10.1016\/j.jacep.2021.02.002","journal-title":"JACC Clin Electrophysiol"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.030356","article-title":"Body mass index and clinical outcomes in Asian patients with atrial fibrillation receiving oral anticoagulation","volume":"52","author":"Lee SR","year":"2021","unstructured":"Lee SR, Choi EK, Jung JH, Park SH, Han KD, Oh S, Lip GY. Body mass index and clinical outcomes in Asian patients with atrial fibrillation receiving oral anticoagulation. Stroke. 2021, 52:521-30. 10.1161\/STROKEAHA.120.030356","journal-title":"Stroke"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01724-8","article-title":"Use of non-vitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and multimorbidity","volume":"38","author":"Deitelzweig S","year":"2021","unstructured":"Deitelzweig S, Keshishian A, Kang A, et al.. Use of non-vitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and multimorbidity. Adv Ther. 2021, 38:3166-84. 10.1007\/s12325-021-01724-8","journal-title":"Adv Ther"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.033470","article-title":"Clinical outcomes in atrial fibrillation patients with a history of cancer treated with non-vitamin K antagonist oral anticoagulants: a nationwide cohort study","volume":"52","author":"Chan YH","year":"2021","unstructured":"Chan YH, Chao TF, Lee HF, et al.. Clinical outcomes in atrial fibrillation patients with a history of cancer treated with non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Stroke. 2021, 52:3132-41. 10.1161\/STROKEAHA.120.033470","journal-title":"Stroke"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.885548","article-title":"Efficacy and safety of oral anticoagulants for atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis","volume":"9","author":"Rhee TM","year":"2022","unstructured":"Rhee TM, Lee SR, Choi EK, Oh S, Lip GY. Efficacy and safety of oral anticoagulants for atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis. Front Cardiovasc Med. 2022, 9:885548. 10.3389\/fcvm.2022.885548","journal-title":"Front Cardiovasc Med"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12083","article-title":"Safety and effectiveness of apixaban compared to warfarin in dialysis patients","volume":"2","author":"Reed D","year":"2018","unstructured":"Reed D, Palkimas S, Hockman R, Abraham S, Le T, Maitland H. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost. 2018, 2:291-8. 10.1002\/rth2.12083","journal-title":"Res Pract Thromb Haemost"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000972","article-title":"Outcomes associated with apixaban vs warfarin in patients with renal dysfunction","volume":"4","author":"Hanni C","year":"2020","unstructured":"Hanni C, Petrovitch E, Ali M, et al.. Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. Blood Adv. 2020, 4:2366-71. 10.1182\/bloodadvances.2019000972","journal-title":"Blood Adv"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.628","article-title":"Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis","volume":"56","author":"Wang X","year":"2016","unstructured":"Wang X, Tirucherai G, Marbury TC, et al.. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016, 56:628-36. 10.1002\/jcph.628","journal-title":"J Clin Pharmacol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.752468","article-title":"Apixaban vs. warfarin in atrial fibrillation patients with chronic kidney disease","volume":"8","author":"Fu CM","year":"2021","unstructured":"Fu CM, Li LC, Lee YT, Wang SW, Hsu CN. Apixaban vs. warfarin in atrial fibrillation patients with chronic kidney disease. Front Cardiovasc Med. 2021, 8:752468. 10.3389\/fcvm.2021.752468","journal-title":"Front Cardiovasc Med"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.01.028","article-title":"A propensity score matched comparison of clinical outcomes in atrial fibrillation patients taking vitamin K antagonists: comparing the \"real-world\" vs clinical trials","volume":"93","author":"Rivera-Caravaca JM","year":"2018","unstructured":"Rivera-Caravaca JM, Esteve-Pastor MA, Mar\u00edn F, Vald\u00e9s M, Vicente V, Rold\u00e1n V, Lip GY. A propensity score matched comparison of clinical outcomes in atrial fibrillation patients taking vitamin K antagonists: comparing the \"real-world\" vs clinical trials. Mayo Clin Proc. 2018, 93:1065-73. 10.1016\/j.mayocp.2018.01.028","journal-title":"Mayo Clin Proc"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip GY","year":"2018","unstructured":"Lip GY, Keshishian A, Li X, et al.. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018, 49:2933-44. 10.1161\/STROKEAHA.118.020232","journal-title":"Stroke"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.025536","article-title":"Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation","volume":"50","author":"Lee SR","year":"2019","unstructured":"Lee SR, Choi EK, Kwon S, et al.. Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation. Stroke. 2019, 50:2245-9. 10.1161\/STROKEAHA.119.025536","journal-title":"Stroke"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.04.108","article-title":"Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation","volume":"156","author":"Chan YH","year":"2019","unstructured":"Chan YH, Lee HF, See LC, et al.. Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation. Chest. 2019, 156:529-43. 10.1016\/j.chest.2019.04.108","journal-title":"Chest"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study","volume":"175","author":"Lau WC","year":"2022","unstructured":"Lau WC, Torre CO, Man KK, et al.. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study. Ann Intern Med. 2022, 175:1515-24. 10.7326\/M22-0511","journal-title":"Ann Intern Med"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17884","article-title":"Oral anticoagulants and outcomes in adults \u226580 years with atrial fibrillation: a global federated health network analysis","volume":"70","author":"Harrison SL","year":"2022","unstructured":"Harrison SL, Buckley BJ, Ritchie LA, Proietti R, Underhill P, Lane DA, Lip GY. Oral anticoagulants and outcomes in adults \u226580 years with atrial fibrillation: a global federated health network analysis. J Am Geriatr Soc. 2022, 70:2386-92. 10.1111\/jgs.17884","journal-title":"J Am Geriatr Soc"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2021.02.018","article-title":"Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation","volume":"18","author":"Chao TF","year":"2021","unstructured":"Chao TF, Chiang CE, Chan YH, Liao JN, Chen TJ, Lip GY, Chen SA. Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation. Heart Rhythm. 2021, 18:871-7. 10.1016\/j.hrthm.2021.02.018","journal-title":"Heart Rhythm"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249524","article-title":"Atrial fibrillation and comorbidities: clinical characteristics and antithrombotic treatment in GLORIA-AF","volume":"16","author":"Kozie\u0142 M","year":"2021","unstructured":"Kozie\u0142 M, Teutsch C, Halperin JL, et al.. Atrial fibrillation and comorbidities: clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS One. 2021, 16:e0249524. 10.1371\/journal.pone.0249524","journal-title":"PLoS One"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American College of Chest Physicians Clinical Practice Guideline","volume":"162","author":"Douketis JD","year":"2022","unstructured":"Douketis JD, Spyropoulos AC, Murad MH, et al.. Perioperative management of antithrombotic therapy: an American College of Chest Physicians Clinical Practice Guideline. Chest. 2022, 162:e207-43. 10.1016\/j.chest.2022.07.025","journal-title":"Chest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/387616-clinical-perspectives-on-stroke-prevention-in-patients-with-non-valvular-atrial-fibrillation-in-the-philippines","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T12:40:47Z","timestamp":1755348047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/387616-clinical-perspectives-on-stroke-prevention-in-patients-with-non-valvular-atrial-fibrillation-in-the-philippines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":138,"URL":"https:\/\/doi.org\/10.7759\/cureus.90214","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,16]]}}}